Diaceutics maintains FY targets with 22% revenue growth in H1

Diaceutics PLC (DXRX) reported H1 2025 revenue of £14.6 million, an 18% increase, and maintained its full-year target of 25% revenue growth despite a recent slowdown in the period. The company significantly advanced its shift to a recurring revenue model, with 70% of H1 revenues now recurring and an order book providing 79% visibility on full-year consensus estimates. While gross cash declined, Diaceutics achieved positive H1 adjusted EBITDA and anticipates full-year earnings profitability, reinforcing its stable operational performance and improved revenue quality.

Analysis

Diaceutics PLC (DXRX) reported a solid first half for 2025, with revenue reaching £14.6 million, an 18% reported increase and 22% at constant currency. Despite a deceleration in growth in the final two months of the period compared to the 35% rate seen through April, management has confidently reiterated its full-year guidance for 25% revenue growth. A key strategic positive is the accelerated shift to a subscription-based model, with recurring revenue now comprising approximately 70% of H1 revenues, up significantly from 55% in fiscal 2024. This transition enhances earnings quality and is supported by a robust order book of £29.4 million, which provides 79% visibility on full-year consensus revenue estimates—a notable improvement from 71% at the same point last year. The company achieved positive adjusted EBITDA in H1 and remains on track for full-year profitability. The primary point of concern is the decline in gross cash to £10.4 million from £12.7 million at year-end; however, management anticipates a recovery in H2 and targets at least free cash flow break-even for the full year.

Key Decisions for Investors

• Investors should view the successful shift to a recurring revenue model, now at 70% of H1 sales, and the 79% visibility on full-year targets as primary indicators of operational strength, despite a noted slowdown in growth during the last two months of the period.
• It is critical to monitor the company's cash position closely in the second half, as management's ability to deliver on its forecast of at least free cash flow break-even for the full year will be a key test of financial discipline.
• Given that management has reaffirmed guidance, focus now shifts to H2 execution; meeting the full-year 25% growth target and returning to net profitability as per market consensus would validate the current positive outlook.